Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2022
2021
2020
Profitability Metrics
Gross Margin
101.90%
Operating Margin
91.23%
Net Margin
96.67%
Efficiency Metrics
Revenue per Expense Ratio
4.73
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
121.46%
Income Tax Rate
0.00%
EPS
2.1100000000
Balance Sheet Analysis
Current Ratio
0.17
Cash Ratio
0.10
Working Capital
$-111.77M
Debt to Equity
0.55
Debt to Assets
34.10%
Equity Ratio
61.98%
Cash Flow Analysis
Operating Cash Flow Ratio
64.72%
Free Cash Flow Ratio
64.72%
CapEx to Revenue
0.00%
Dividends Paid
$38.79M
Stock Buybacks
$37.10M
Total Shareholder Returns
$75.88M
Cash Position Change
50.78%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 40.41%
Detailed Growth Metrics
Core Performance
Revenue
269.78%
Net Income
270.67%
EPS
313.73%
Operating Income
17.64%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
47.88%
Operating Cash Flow
27.87%
Free Cash Flow
27.87%
Balance Sheet Health
Assets
-3.02%
Debt
62.71%
Book Value per Share
4.82%
Inventory
-100.99%
Shareholder Returns
Dividends per Share
40.41%
Shares Outstanding
-9.91%
Long Term Trends
3Y Revenue/Share
-4.64%
5Y Revenue/Share
339.62%
3Y Dividend/Share
101.90%
5Y Dividend/Share
69.33%